Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
Holding GB:HIK?
Track your performance easily

Hikma Pharmaceuticals (HIK) Financial Statements

44 Followers

Hikma Pharmaceuticals Financial Overview

Hikma Pharmaceuticals's market cap is currently ―. The company's EPS TTM is p1.019; its P/E ratio is 17.82; and it has a dividend yield of 3.41%. Hikma Pharmaceuticals is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Jun 22Dec 21Jun 21Dec 20
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 292.00M$ 393.00M$ 450.00M$ 346.00M$ 347.00M
Total Assets$ 4.47B$ 4.75B$ 4.37B$ 4.18B$ 4.13B
Total Debt$ 1.28B$ 1.55B$ 846.00M$ 932.00M$ 932.00M
Net Debt$ 991.00M$ 1.16B$ 396.00M$ 586.00M$ 585.00M
Total Liabilities$ 2.32B$ 2.56B$ 1.91B$ 1.88B$ 1.99B
Stockholders Equity$ 2.13B$ 2.18B$ 2.45B$ 2.29B$ 2.13B
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Hikma Pharmaceuticals Earnings and Revenue History

Hikma Pharmaceuticals Debt to Assets

Hikma Pharmaceuticals Cash Flow

Hikma Pharmaceuticals Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis